Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)
Conditions
Interventions
Burosumab
Locations
9
Austria
Kepler Universitaetsklinikum GmbH
Linz, Austria
Centre de reference des maladies renales rares-Hospices Civils de Lyon-Hopital Femme Mere Enfant
Lyon, France
Hopital Kremlin APHP
Paris, France
Ospedale Pediatrico Bambino Gesù
Rome, Italy
Hospital Virgen del Rocío
Seville, Spain
Karolinska University Hospital
Stockholm, Sweden
Start Date
February 26, 2020
Primary Completion Date
October 4, 2023
Completion Date
March 6, 2024
Last Updated
November 7, 2024
NCT04842032
NCT04872907
Lead Sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions